29 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Company Limited
29 May 24
Current report (foreign)
6:29am
litigations related to its products and its activities, the most significant of which are describe below. ACTOS Antitrust Litigation In December 2013 … , the first of two antitrust class action lawsuits was filed against Takeda in the U.S. District Court for the Southern District of New York
6-K
TAK
Takeda Pharmaceutical Company Limited
2 Feb 24
Current report (foreign)
6:16am
, except for the matters below.
Sales, Marketing, and Regulation
COLCRYS Antitrust Litigation
In September 2021, an antitrust class action was filed … the antitrust matter for an amount that is immaterial, which was fully executed in December 2023. The settlement had no material impact on Takeda’s
6-K
EX-99.1
t0i2e
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
xy1lv2ub0 hx7
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
vayz4vlts
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
2qwtq scw656q
31 May 22
Current report (foreign)
12:00am
6-K
niad mn2f
10 Feb 22
Current report (foreign)
6:03am
6-K
bqx ro8dgb
5 Nov 21
Current report (foreign)
6:02am
6-K
EX-99.1
bb6er7629oy0yx bg4i
28 May 21
Current report (foreign)
6:03am
6-K
vrxvb x2t5x9ha
24 Jun 20
Current report (foreign)
3:31pm
6-K
ic8r1lqu4
27 May 20
Current report (foreign)
6:05am
424B3
q2qslger
14 Nov 19
Prospectus supplement
6:10am
F-4/A
kn1hzvixqx uhz2gb
12 Nov 19
Registration of securities (foreign) (amended)
9:50am
F-4
p83i31dgozecp57nw
9 Aug 19
Registration of securities (foreign)
6:27am